MENU
+Compare
LGND
Stock ticker: NASDAQ
AS OF
Mar 28 closing price
Price
$107.62
Change
-$2.08 (-1.90%)
Capitalization
2.07B

LGND stock forecast, quote, news & analysis

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine... Show more

Industry: #Biotechnology
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for LGND with price predictions
Mar 28, 2025

LGND in -3.21% downward trend, sliding for three consecutive days on March 26, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where LGND declined for three days, in of 280 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

LGND moved below its 50-day moving average on March 10, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LGND crossed bearishly below the 50-day moving average on March 12, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 57 cases where LGND's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on March 24, 2025. You may want to consider a long position or call options on LGND as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LGND just turned positive on March 24, 2025. Looking at past instances where LGND's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in of 332 cases, the price rose further within the following month. The odds of a continued upward trend are .

LGND may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 214 cases where LGND Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.496) is normal, around the industry mean (14.015). P/E Ratio (46.189) is within average values for comparable stocks, (64.855). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.895). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (11.779) is also within normal values, averaging (257.708).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Dividends

LGND paid dividends on July 01, 2010

Ligand Pharmaceuticals LGND Stock Dividends
А quarterly dividend of $0.12 per share was paid with a record date of July 01, 2010, and an ex-dividend date of July 02, 2010. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 151 to 307.16B. NONOF holds the highest valuation in this group at 307.16B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -10%. OMGAQ experienced the highest price growth at 519%, while MYNDF experienced the biggest fall at -84%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was 181%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 70
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a biotechnology company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
555 Heritage Drive
Phone
+1 858 550-7500
Employees
58
Web
https://www.ligand.com